OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis $0.01 0.00 (0.00%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About CV Sciences Stock (OTCMKTS:CVSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CV Sciences alerts:Sign Up Key Stats Today's Range$0.0130▼$0.014050-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.10Volume72,046 shsAverage Volume831,077 shsMarket Capitalization$3.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CV Sciences, Inc. is a life sciences company focused on hemp-derived cannabidiol (CBD) consumer products. The company develops, manufactures, and markets products under its PlusCBD brand, including CBD oils, softgels, gummies, capsules, topicals, and products formulated for pets. PlusCBD products are positioned for use in areas such as general wellness, relaxation, sleep, and recovery. CV Sciences distributes its products through e-commerce channels and a network of retail outlets, primarily in the United States, subject to applicable regulations governing hemp-derived products and dietary supplements. Founded in 2012, CV Sciences has historically focused on cannabinoid-based consumer health products and related research. The company has been led by Joseph Dowling, who has served as its chief executive officer. Its shares trade on the over-the-counter market under the symbol CVSI.AI Generated. May Contain Errors. Read More CV Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreCVSI MarketRank™: CV Sciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CV Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCV Sciences has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 123.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCV Sciences does not currently pay a dividend.Dividend GrowthCV Sciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CV Sciences this week, compared to 0 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CV Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of CV Sciences is held by insiders.Percentage Held by InstitutionsCV Sciences has minimal institutional ownership at this time.Read more about CV Sciences' insider trading history. Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVSI Stock News HeadlinesCV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory FrameworkSeptember 8, 2026 | theglobeandmail.comCV Sciences, Inc. (CVSI) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | seekingalpha.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 9 at 1:00 AM | Banyan Hill Publishing (Ad)CV Sciences, Inc.: CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond CannabinoidsAugust 12, 2026 | finanznachrichten.deCV Sciences Shareholders Elect Directors, Reject Reverse Stock SplitJune 4, 2026 | tipranks.comCV Sciences, Inc. (CVSI) Shareholder/Analyst Call Prepared Remarks TranscriptJune 2, 2026 | seekingalpha.comCV Sciences Inc (CVSI) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...May 15, 2026 | finance.yahoo.comCV Sciences, Inc. (CVSI) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comSee More Headlines CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed this year? CV Sciences' stock was trading at $0.0614 at the beginning of 2026. Since then, CVSI stock has decreased by 77.2% and is now trading at $0.0140. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.03). The business earned $5.13 million during the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 132.06% and a negative net margin of 15.74%. How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), Kushco (KSHB), NVIDIA (NVDA) and Organigram Global (OGI). Company Calendar Last Earnings8/12/2021Today10/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees43Year Founded2016Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$960 thousand Net Margins-15.74% Pretax Margin-15.69% Return on Equity-132.06% Return on Assets-29.50% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.18 Sales & Book Value Annual Sales$13.79 million Price / Sales0.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book1.40Miscellaneous Outstanding Shares235,694,000Free Float219,903,000Market Cap$3.30 million OptionableNot Optionable Beta0.43 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:CVSI) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CV Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
